His main research concerns Multiple myeloma, Internal medicine, Surgery, Oncology and Bortezomib. The concepts of his Multiple myeloma study are interwoven with issues in Bone marrow and Dexamethasone. His research integrates issues of Gastroenterology and Immunology in his study of Internal medicine.
His work deals with themes such as Risk factor and Hazard ratio, which intersect with Surgery. His studies deal with areas such as Interleukin 6, Leukemia, Refractory and MEDLINE as well as Oncology. His biological study spans a wide range of topics, including Proteasome inhibitor, Urology, Kidney disease and Renal function.
Heinz Ludwig mostly deals with Internal medicine, Multiple myeloma, Oncology, Surgery and Gastroenterology. In most of his Internal medicine studies, his work intersects topics such as Immunology. The various areas that Heinz Ludwig examines in his Multiple myeloma study include Bone marrow and Dexamethasone.
His studies in Oncology integrate themes in fields like Hematology, Clinical trial and Maintenance therapy. His work in Surgery addresses issues such as Urology, which are connected to fields such as Renal function. His Bortezomib research is multidisciplinary, relying on both Proteasome inhibitor and Refractory.
Heinz Ludwig spends much of his time researching Multiple myeloma, Internal medicine, Oncology, Lenalidomide and Carfilzomib. His Multiple myeloma research is multidisciplinary, incorporating perspectives in Adverse effect, Clinical trial, Surgery and Intensive care medicine. Dexamethasone, Bortezomib, Thalidomide, Hematology and Hazard ratio are the subjects of his Internal medicine studies.
His Oncology research focuses on Newly diagnosed and how it relates to Intensification therapy. His study in Lenalidomide is interdisciplinary in nature, drawing from both Transplantation, Melphalan, Clinical endpoint and Phases of clinical research. The Carfilzomib study which covers Randomized controlled trial that intersects with Quality of life.
His primary areas of investigation include Multiple myeloma, Internal medicine, Lenalidomide, Oncology and Clinical trial. Heinz Ludwig interconnects Adverse effect, Minimal residual disease, Intensive care medicine, Disease and Transplantation in the investigation of issues within Multiple myeloma. Internal medicine is closely attributed to Surgery in his work.
His work carried out in the field of Lenalidomide brings together such families of science as Thalidomide, Melphalan, Phases of clinical research, Intensification therapy and Hazard ratio. His research in Clinical trial intersects with topics in Randomized controlled trial and Monoclonal antibody, Daratumumab. His work is dedicated to discovering how Dexamethasone, Proteasome inhibitor are connected with Elotuzumab and other disciplines.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International uniform response criteria for multiple myeloma
B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade.
International staging system for multiple myeloma.
Philip R. Greipp;Jesus San Miguel;Brian G.M. Durie;John J. Crowley.
Journal of Clinical Oncology (2005)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer;Igor Bondarenko;Anatoly Makhson;Joerg T. Hartmann.
Journal of Clinical Oncology (2009)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)
The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
Heinz Ludwig;Simon Van Belle;Peter Barrett-Lee;Gunnar Birgegård.
European Journal of Cancer (2004)
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel.
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo;S. V. Rajkumar;M. A. Dimopoulos;P. G. Richardson.
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar;Jean Luc Harousseau;Brian Durie;Kenneth C. Anderson.
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
R A Kyle;B G M Durie;S V Rajkumar;O Landgren.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua.
Lancet Oncology (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: